Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 18;13(1):54.
doi: 10.1038/s41408-023-00827-5.

A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications

Dima El-Sharkawi #  1 , Amit Sud #  1   2 , Catherine Prodger  3 , Jahanzaib Khwaja  4 , Rohan Shotton  5 , Brian Hanley  6 , Victoria Peacock  7 , Ying Ying Peng  8 , Anita Arasaretnam  9 , Sarkhara Sharma  1 , Frances Aldridge  1 , Bhupinder Sharma  1 , Andrew Wotherspoon  1 , Betty Cheung  10 , Corinne De Lord  11 , Rosalynd Johnston  9 , Shireen Kassam  7 , Ruth Pettengel  8 , Kim Linton  5 , Paul Greaves  12 , Lucy Cook  6 , Kikkeri N Naresh  6 , Kate Cwynarski  4 , Toby A Eyre  3 , Ian Chau  1 , David Cunningham  1 , Sunil Iyengar  13
Affiliations

A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications

Dima El-Sharkawi et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Kaplan–Meier estimates for overall survival and time to next treatment for Myc rearranged DLBCL patients in this study.
A Overall survival in all patients, including MYC-BCL2 double hit and triple hit, MYC rearranged and MYC-BCL6 diffuse large B-cell lymphoma; B overall survival for patients with MYC-BCL2 double hit and triple hit, MYC rearranged and MYC-BCL6 diffuse large B-cell lymphoma treated with all types of chemoimmunotherapy; C time to next treatment for patients with MYC-BCL2 double hit and triple hit, MYC rearranged and MYC-BCL6 diffuse large B-cell lymphoma treated with all types of chemoimmunotherapy; D overall survival for patients treated with RCHOP or intensive therapy stratified by MYC-BCL2 double hit and triple hit, MYC rearranged and MYC-BCL6 translocation status; E time to next treatment for patients treated with R-CHOP or intensive therapy stratified by MYC-BCL2 double hit and triple hit, MYC rearranged and MYC-BCL6 translocation status; F overall survival in all patients with MYC-BCL2 double hit and triple hit diffuse large B-cell lymphoma stratified by treatment with RCHOP or intensive therapy; G time to next treatment in all patients with MYC-BCL2 double hit and triple hit diffuse large B-cell lymphoma stratified by treatment with RCHOP or intensive therapy.
See this image and copyright information in PMC

References

    1. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl J Med. 2018;378:1396–407. doi: 10.1056/NEJMoa1801445. - DOI - PMC - PubMed
    1. Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171:481–94.e415. doi: 10.1016/j.cell.2017.09.027. - DOI - PMC - PubMed
    1. Arthur SE, Jiang A, Grande BM, Alcaide M, Cojocaru R, Rushton CK, et al. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat Commun. 2018;9:4001. doi: 10.1038/s41467-018-06354-3. - DOI - PMC - PubMed
    1. Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2018;32:675–84. doi: 10.1038/leu.2017.251. - DOI - PMC - PubMed
    1. Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135:1759–71. doi: 10.1182/blood.2019003535. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances